PL4208151T3 - Liofilizowane aktywne kompozycje proszku o niskiej higroskopijności - Google Patents

Liofilizowane aktywne kompozycje proszku o niskiej higroskopijności

Info

Publication number
PL4208151T3
PL4208151T3 PL21763144.9T PL21763144T PL4208151T3 PL 4208151 T3 PL4208151 T3 PL 4208151T3 PL 21763144 T PL21763144 T PL 21763144T PL 4208151 T3 PL4208151 T3 PL 4208151T3
Authority
PL
Poland
Prior art keywords
freeze dried
powder compositions
low hygroscopicity
active powder
dried low
Prior art date
Application number
PL21763144.9T
Other languages
English (en)
Inventor
Fabiana SPADARO
Gerard Zuber
Original Assignee
Philip Morris Products S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Philip Morris Products S.A. filed Critical Philip Morris Products S.A.
Publication of PL4208151T3 publication Critical patent/PL4208151T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1617Organic compounds, e.g. phospholipids, fats
    • A61K9/1623Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/452Piperidinium derivatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465Nicotine; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682Processes
    • A61K9/1694Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00Inhalators
    • A61M15/0028Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
    • A61M15/003Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using capsules, e.g. to be perforated or broken-up
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00Inhalators
    • A61M15/0028Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
    • A61M15/003Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using capsules, e.g. to be perforated or broken-up
    • A61M15/0033Details of the piercing or cutting means
    • A61M15/0035Piercing means
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00Inhalators
    • A61M15/06Inhaling appliances shaped like cigars, cigarettes or pipes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00Special media to be introduced, removed or treated
    • A61M2202/06Solids
    • A61M2202/064Powder

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Anesthesiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Otolaryngology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Medicinal Preparation (AREA)
PL21763144.9T 2020-09-03 2021-08-31 Liofilizowane aktywne kompozycje proszku o niskiej higroskopijności PL4208151T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20194435 2020-09-03
PCT/IB2021/057951 WO2022049486A1 (en) 2020-09-03 2021-08-31 Freeze dried low hygroscopicity active powder compositions

Publications (1)

Publication Number Publication Date
PL4208151T3 true PL4208151T3 (pl) 2024-11-04

Family

ID=72380904

Family Applications (1)

Application Number Title Priority Date Filing Date
PL21763144.9T PL4208151T3 (pl) 2020-09-03 2021-08-31 Liofilizowane aktywne kompozycje proszku o niskiej higroskopijności

Country Status (10)

Country Link
US (1) US20230301919A1 (pl)
EP (1) EP4208151B1 (pl)
JP (1) JP2023540191A (pl)
KR (1) KR20230079011A (pl)
CN (1) CN116033891A (pl)
BR (1) BR112023003114A2 (pl)
ES (1) ES2985415T3 (pl)
MX (1) MX2023002465A (pl)
PL (1) PL4208151T3 (pl)
WO (1) WO2022049486A1 (pl)

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2007012991A (es) * 2005-04-20 2008-03-13 Metabolex Inc Formas solidas cristalinas y amorfas de halofenato (-) y metodoss relacionados a las mismas.
JP2011500724A (ja) * 2007-10-19 2011-01-06 パーデュ リサーチ ファンデーション 結晶性化合物の固体製剤
WO2011112689A2 (en) * 2010-03-11 2011-09-15 Ambit Biosciences Corp. Saltz of an indazolylpyrrolotriazine
US8207346B2 (en) 2010-03-23 2012-06-26 Rock Creek Pharmaceuticals, Inc. Methods of synthesizing anatabine
EP2549995B1 (en) 2010-03-23 2021-04-21 Philip Morris Products S.A. Use of anatabine to treat inflammation and methods of synthesizing anatabine
US20120245202A1 (en) * 2010-09-17 2012-09-27 Rock Creek Pharmaceuticals, Inc. Methods and products for treating inflammation
WO2013032558A2 (en) 2011-08-29 2013-03-07 Rock Creek Pharmaceuticals, Inc. Products for anti-inflammation support
WO2018002756A1 (en) * 2016-06-30 2018-01-04 Philip Morris Products S.A. Nicotine particles and compositions
EP3592352A1 (en) * 2017-03-07 2020-01-15 Philip Morris Products S.a.s. Inhalable nicotine formulations, and methods of making and using thereof
KR20210038583A (ko) * 2018-07-24 2021-04-07 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 초고속 동결에 의해 표면 변성된 치료적 활성 입자의 조성물
IL283923B2 (en) 2018-12-17 2025-08-01 Philip Morris Products Sa 3-(1,2,3,6-tetrahydropyridin-2-yl)pyridine glutarate or a pharmaceutically acceptable solvate thereof

Also Published As

Publication number Publication date
CN116033891A (zh) 2023-04-28
KR20230079011A (ko) 2023-06-05
ES2985415T3 (es) 2024-11-05
BR112023003114A2 (pt) 2023-04-04
EP4208151B1 (en) 2024-07-10
US20230301919A1 (en) 2023-09-28
MX2023002465A (es) 2023-03-23
WO2022049486A1 (en) 2022-03-10
JP2023540191A (ja) 2023-09-22
EP4208151C0 (en) 2024-07-10
EP4208151A1 (en) 2023-07-12

Similar Documents

Publication Publication Date Title
HK1251466A1 (zh) 包含pi3k抑制剂和hdac抑制剂的组合物
AU2016245785A8 (en) Synergistic preservative compositions
PL4135520T3 (pl) Kombinacje związków aktywnych i kompozycje grzybobójcze je zawierające
HUE069426T2 (hu) Hatóanyag-kombinációk és ezeket tartalmazó fungicid készítmények
PL4384016T3 (pl) Kombinacje związków aktywnych i kompozycje grzybobójcze je zawierające
LT4135521T (lt) Veikliųjų medžiagų deriniai ir juos apimančios fungicidų kompozicijos
HUE069397T2 (hu) Hatóanyag-kombinációk és azokat tartalmazó fungicid készítmények
HUE069153T2 (hu) Hatóanyag-kombinációk és azokat tartalmazó fungicid készítmények
PL4057845T3 (pl) Ulepszony preparat w postaci suchego proszku o aromacie tytoniowym
SG11202111488YA (en) Solid pharmaceutical composition comprising tlr7 agonist
ZA202101714B (en) Melt-castable active explosive composition
PH12017501444A1 (en) (2r,4r)-5-(5`-chloro-2`-fluorobiphenyl-4-yl)-2-hydroxy-4-[(5-methyloxazole-2-carbonyl)amino]pentanoic acid
GB202117602D0 (en) Solid composition
PL4208151T3 (pl) Liofilizowane aktywne kompozycje proszku o niskiej higroskopijności
HUE072114T2 (hu) Alacsony higroszkópikájú aktív porkészítmények
GB202204335D0 (en) Non-antibiotic antimicrobial compositions
EP4321166A4 (en) COMPOSITION FOR INHIBITING A BIOFILM COMPRISING LACTOBACILLUS RHAMNOSUS AS AN ACTIVE INGREDIENT
EP4319541A4 (en) HARVESTING DEVICE FOR COMBINE HARVESTING RESIDUE SPREADER RIB SHAPED TO INCREASE SPREADING EFFECT
HUE071569T2 (hu) Sppl2a inhibitor vegyületek és készítmények
ZA202303733B (en) Agricultural composition
IL292979B2 (en) Stable preparations of antifungal compounds
GB202307579D0 (en) Freeze dried microplant composition
EP3903805A4 (en) COMPOSITION OF OR ENHANCEMENT OF ANTI-CANCER OR IMMUNOSTIMULATING ACTIVITY COMPRISING A MAL-EXPRESSED STEM CELL-LIKE MEMORY T CELL AS AN ACTIVE INGREDIENT
GB202204668D0 (en) Active compositions
KR101761061B9 (ko) 키토산­페룰산 염 화합물의 제조방법 및 이로부터 제조된 키토산­페룰산 염 화합물을 유효성분으로 함유하는 항균성 조성물